

Applicants: Ron S. Israeli et al.
Serial No.: 08/470,735
Filed: June 6, 1995
Page 2

Please amend the subject application as follows:

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1-127. (Canceled)

128. (Currently Amended) A purified monoclonal antibody which binds to a fragment of an outer membrane domain of prostate specific membrane antigen, which fragment has within its structure the consecutive amino acid sequence Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID NO: 35).

129. (Currently Amended) A purified monoclonal antibody which binds to a fragment of an outer membrane domain of prostate specific membrane antigen, which fragment has within its structure the consecutive amino acid sequence Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID NO: 36).

130. (Currently Amended) A purified monoclonal antibody which binds to a fragment of an outer membrane domain of prostate specific membrane antigen, which fragment has within its structure the consecutive amino acid sequence Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID NO: 37).

131. (Currently Amended) A purified monoclonal antibody which binds to a fragment of an outer membrane domain of prostate specific membrane antigen, which fragment has within its structure each of the following amino acid sequences:

- (a) Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID NO: 35);
- (b) Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID NO: 36);
- (c) Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID NO: 37); and
- (d) Ala-Gly-Ala-Leu-Val-Leu-Ala-Gly-Gly-Phe-Phe-Leu-Leu-Gly-Phe-Leu-Phe (SEQ ID NO:38).

132. (Currently Amended) A purified monoclonal antibody which binds to a fragment of an outer membrane domain of prostate specific membrane antigen, which fragment has within its structure each of the following amino acid sequences:

- (a) Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID NO: 35);
- (b) Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID NO: 36); and
- (c) Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID NO: 37).

133. (Currently Amended) A purified monoclonal antibody which binds to a fragment of prostate specific membrane antigen, which fragment corresponds to a hydrophilic region of an outer membrane domain of prostate specific membrane antigen, the amino acid sequence of which antigen is set forth in SEQ ID NO:2.

134. (Currently Amended) A purified monoclonal antibody which binds to a hydrophilic region of an outer

membrane domain of prostate specific membrane antigen, which hydrophilic region has within its structure the consecutive amino acid sequence Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID NO: 35).

135. (Currently Amended) A purified monoclonal antibody which binds to a hydrophilic region of an outer membrane domain of prostate specific membrane antigen, which hydrophilic region has within its structure the consecutive amino acid sequence Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID NO: 36).

136. (Currently Amended) A purified monoclonal antibody which binds to a hydrophilic region of an outer membrane domain of prostate specific membrane antigen, which hydrophilic region has within its structure the consecutive amino acid sequence Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID NO: 37).

137. (Currently Amended) A purified monoclonal antibody which binds to an outer membrane domain of prostate specific membrane antigen, the amino acid sequence of which antigen is set forth in SEQ ID NO:2.

138. (Currently Amended) A purified monoclonal antibody which binds to a hydrophilic region of an outer membrane domain of prostate specific membrane antigen, the amino acid sequence of which antigen is set forth in SEQ ID NO:2.

139. (Canceled)

Applicants: Ron S. Israeli et al.
Serial No.: 08/470,735
Filed: June 6, 1995
Page 5

140. (Canceled)

141. (Currently Amended) A composition of matter comprising the monoclonal antibody of any one of claims 128-138 and an agent conjugated to the monoclonal antibody.

142. (Previously Presented) The composition of matter of claim 141, wherein the agent is a radioisotope or toxin.

143. (Previously Presented) A composition comprising a carrier and the composition of matter of claim 141.

144. (Previously Presented) A method of imaging prostate cancer in a subject which comprises administering to the subject the composition of matter of claim 141, wherein the agent is an imaging agent under conditions permitting formation of a complex between the composition of matter and prostate specific membrane antigen, and obtaining an image of any complex so formed.

145.-160. (Canceled)

161. (Previously Presented) A monoclonal antibody having an antigen-binding region specific for the extracellular domain of prostate specific membrane antigen, the amino acid sequence of which antigen is set forth in SEQ ID NO:2.

Applicants: Ron S. Israeli et al.
Serial No.: 08/470,735
Filed: June 6, 1995
Page 6

162. (Canceled)

163. (Canceled)